Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Care | 20 | 2022 | 644 | 4.700 |
Why?
|
| Heart Defects, Congenital | 26 | 2022 | 1776 | 3.780 |
Why?
|
| Cardiopulmonary Bypass | 14 | 2021 | 342 | 3.530 |
Why?
|
| Cardiac Surgical Procedures | 17 | 2024 | 1086 | 2.550 |
Why?
|
| Pediatrics | 12 | 2022 | 1132 | 2.440 |
Why?
|
| Hemodynamics | 14 | 2023 | 833 | 2.230 |
Why?
|
| Critical Illness | 11 | 2023 | 587 | 2.180 |
Why?
|
| Monitoring, Physiologic | 11 | 2022 | 356 | 1.860 |
Why?
|
| Oxygen | 8 | 2021 | 537 | 1.730 |
Why?
|
| Intensive Care Units, Pediatric | 9 | 2021 | 469 | 1.590 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 188 | 1.570 |
Why?
|
| Cardiology | 4 | 2017 | 463 | 1.570 |
Why?
|
| Oximetry | 7 | 2021 | 157 | 1.450 |
Why?
|
| Heart Failure | 8 | 2016 | 2123 | 1.420 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2021 | 129 | 1.420 |
Why?
|
| Capnography | 2 | 2020 | 13 | 1.310 |
Why?
|
| Cardiovascular System | 2 | 2023 | 99 | 1.310 |
Why?
|
| Heart Diseases | 4 | 2019 | 480 | 1.260 |
Why?
|
| Sepsis | 2 | 2023 | 471 | 1.240 |
Why?
|
| Child | 46 | 2022 | 23950 | 1.050 |
Why?
|
| Nitric Oxide | 5 | 2019 | 446 | 1.030 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2017 | 274 | 0.990 |
Why?
|
| Cardiac Output | 7 | 2022 | 168 | 0.960 |
Why?
|
| Physicians | 3 | 2022 | 580 | 0.930 |
Why?
|
| Humans | 84 | 2024 | 121045 | 0.930 |
Why?
|
| Arginine Vasopressin | 1 | 2023 | 28 | 0.890 |
Why?
|
| Heart | 4 | 2023 | 718 | 0.860 |
Why?
|
| Blood Pressure | 6 | 2022 | 1310 | 0.830 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2014 | 621 | 0.820 |
Why?
|
| Hypertension, Pulmonary | 5 | 2019 | 422 | 0.800 |
Why?
|
| Cerebrovascular Circulation | 3 | 2021 | 429 | 0.780 |
Why?
|
| Certification | 2 | 2019 | 69 | 0.780 |
Why?
|
| Tetralogy of Fallot | 3 | 2012 | 160 | 0.780 |
Why?
|
| Postoperative Complications | 8 | 2020 | 2869 | 0.780 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2021 | 152 | 0.770 |
Why?
|
| Inflammation | 2 | 2020 | 1396 | 0.770 |
Why?
|
| Lung | 2 | 2020 | 1461 | 0.760 |
Why?
|
| Fontan Procedure | 1 | 2023 | 181 | 0.750 |
Why?
|
| Acute Kidney Injury | 3 | 2017 | 590 | 0.720 |
Why?
|
| Heart-Assist Devices | 3 | 2022 | 1022 | 0.720 |
Why?
|
| Natriuretic Agents | 2 | 2017 | 31 | 0.710 |
Why?
|
| Infant, Newborn | 17 | 2022 | 7976 | 0.700 |
Why?
|
| Infant | 24 | 2020 | 12201 | 0.670 |
Why?
|
| Triiodothyronine | 1 | 2019 | 64 | 0.660 |
Why?
|
| Internationality | 1 | 2019 | 126 | 0.640 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 310 | 0.630 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 505 | 0.620 |
Why?
|
| Postoperative Care | 5 | 2020 | 293 | 0.610 |
Why?
|
| Hypothyroidism | 1 | 2019 | 89 | 0.610 |
Why?
|
| Respiratory Tract Diseases | 2 | 2016 | 77 | 0.610 |
Why?
|
| Curriculum | 2 | 2022 | 710 | 0.600 |
Why?
|
| Hospital Mortality | 5 | 2021 | 976 | 0.580 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 2779 | 0.570 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 164 | 0.570 |
Why?
|
| Vasopressins | 3 | 2021 | 42 | 0.560 |
Why?
|
| Carbon Dioxide | 2 | 2020 | 274 | 0.560 |
Why?
|
| Immunomodulation | 1 | 2016 | 79 | 0.530 |
Why?
|
| Respiratory System | 1 | 2016 | 95 | 0.520 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 103 | 0.510 |
Why?
|
| Societies, Medical | 5 | 2015 | 662 | 0.510 |
Why?
|
| Clinical Competence | 2 | 2019 | 966 | 0.500 |
Why?
|
| Shock | 1 | 2016 | 89 | 0.500 |
Why?
|
| Immune System Diseases | 1 | 2015 | 45 | 0.500 |
Why?
|
| Child, Preschool | 18 | 2020 | 13708 | 0.490 |
Why?
|
| Congresses as Topic | 1 | 2015 | 163 | 0.470 |
Why?
|
| Child Abuse | 1 | 2017 | 198 | 0.460 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 266 | 0.450 |
Why?
|
| Education, Medical | 1 | 2017 | 285 | 0.450 |
Why?
|
| Ventilator Weaning | 2 | 2010 | 22 | 0.440 |
Why?
|
| Shock, Septic | 1 | 2015 | 148 | 0.440 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2013 | 42 | 0.440 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 1806 | 0.440 |
Why?
|
| Oxygen Consumption | 2 | 2011 | 302 | 0.420 |
Why?
|
| Vascular Resistance | 2 | 2020 | 189 | 0.420 |
Why?
|
| Vancomycin | 1 | 2014 | 216 | 0.410 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 205 | 0.400 |
Why?
|
| Length of Stay | 6 | 2021 | 1258 | 0.390 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2011 | 12 | 0.390 |
Why?
|
| Airway Extubation | 1 | 2012 | 67 | 0.380 |
Why?
|
| Consensus | 2 | 2011 | 601 | 0.370 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 83 | 0.350 |
Why?
|
| Cardiac Output, Low | 1 | 2010 | 66 | 0.350 |
Why?
|
| Intensive Care Units | 6 | 2020 | 474 | 0.350 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 134 | 0.350 |
Why?
|
| Pituitary-Adrenal System | 1 | 2010 | 36 | 0.340 |
Why?
|
| Brain | 2 | 2012 | 2918 | 0.340 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2010 | 64 | 0.340 |
Why?
|
| Retrospective Studies | 15 | 2022 | 15563 | 0.340 |
Why?
|
| Treatment Outcome | 12 | 2024 | 11680 | 0.340 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 29 | 0.340 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2010 | 78 | 0.330 |
Why?
|
| Coronary Care Units | 4 | 2020 | 36 | 0.320 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 590 | 0.320 |
Why?
|
| Respiration, Artificial | 6 | 2019 | 448 | 0.320 |
Why?
|
| Diuretics | 3 | 2019 | 156 | 0.310 |
Why?
|
| Postoperative Period | 4 | 2019 | 330 | 0.310 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 543 | 0.300 |
Why?
|
| Steroids | 1 | 2009 | 201 | 0.300 |
Why?
|
| Peritoneal Dialysis | 2 | 2020 | 117 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 1023 | 0.280 |
Why?
|
| Arteries | 2 | 2019 | 211 | 0.280 |
Why?
|
| Hospitalization | 5 | 2021 | 1717 | 0.280 |
Why?
|
| Fluid Therapy | 2 | 2022 | 121 | 0.280 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2021 | 147 | 0.270 |
Why?
|
| Dexamethasone | 3 | 2005 | 273 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 278 | 0.260 |
Why?
|
| Prospective Studies | 7 | 2020 | 5854 | 0.250 |
Why?
|
| Administration, Inhalation | 3 | 2019 | 177 | 0.250 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2009 | 308 | 0.250 |
Why?
|
| Respiration | 3 | 2016 | 123 | 0.250 |
Why?
|
| Male | 22 | 2020 | 58908 | 0.240 |
Why?
|
| Creatinine | 2 | 2017 | 377 | 0.230 |
Why?
|
| Female | 22 | 2020 | 63993 | 0.230 |
Why?
|
| Acute Disease | 3 | 2016 | 1086 | 0.230 |
Why?
|
| Heart Rate | 3 | 2020 | 583 | 0.230 |
Why?
|
| Cause of Death | 2 | 2019 | 442 | 0.220 |
Why?
|
| Mediastinum | 1 | 2023 | 41 | 0.220 |
Why?
|
| Time Factors | 6 | 2019 | 5975 | 0.220 |
Why?
|
| Hemodynamic Monitoring | 1 | 2022 | 12 | 0.210 |
Why?
|
| Water | 1 | 2023 | 177 | 0.210 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 215 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 2370 | 0.210 |
Why?
|
| Pain, Postoperative | 1 | 2024 | 251 | 0.190 |
Why?
|
| Vena Cava, Superior | 1 | 2021 | 55 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3209 | 0.180 |
Why?
|
| United States | 6 | 2022 | 10332 | 0.180 |
Why?
|
| Biological Transport | 2 | 2011 | 348 | 0.180 |
Why?
|
| Age Factors | 2 | 2019 | 2760 | 0.180 |
Why?
|
| Tidal Volume | 1 | 2020 | 36 | 0.180 |
Why?
|
| Nicardipine | 1 | 2020 | 18 | 0.180 |
Why?
|
| Nitroprusside | 1 | 2020 | 46 | 0.170 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 52 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 175 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2021 | 3200 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 138 | 0.170 |
Why?
|
| Cardiomyopathies | 2 | 2020 | 476 | 0.170 |
Why?
|
| Heart Septal Defects | 1 | 2019 | 40 | 0.170 |
Why?
|
| Acidosis | 1 | 2020 | 91 | 0.170 |
Why?
|
| Noonan Syndrome | 1 | 2019 | 29 | 0.160 |
Why?
|
| Arginine | 1 | 2021 | 330 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 167 | 0.150 |
Why?
|
| Bronchodilator Agents | 1 | 2019 | 154 | 0.150 |
Why?
|
| Respiratory Insufficiency | 2 | 2012 | 234 | 0.150 |
Why?
|
| Oliguria | 1 | 2017 | 18 | 0.140 |
Why?
|
| Nurses | 1 | 2017 | 62 | 0.140 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 76 | 0.140 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.140 |
Why?
|
| Nephrons | 1 | 2016 | 20 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 429 | 0.140 |
Why?
|
| Diuresis | 1 | 2016 | 58 | 0.140 |
Why?
|
| Adolescent | 6 | 2021 | 18730 | 0.140 |
Why?
|
| Veins | 1 | 2017 | 102 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1672 | 0.140 |
Why?
|
| Reoperation | 1 | 2019 | 772 | 0.130 |
Why?
|
| Risk Factors | 4 | 2020 | 9603 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Inpatients | 1 | 2020 | 479 | 0.130 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 9 | 0.130 |
Why?
|
| Ventricular Pressure | 1 | 2016 | 43 | 0.130 |
Why?
|
| Specialization | 1 | 2016 | 75 | 0.130 |
Why?
|
| Alprostadil | 1 | 2015 | 28 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2019 | 1454 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 731 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 382 | 0.120 |
Why?
|
| Educational Measurement | 1 | 2017 | 319 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 119 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2019 | 766 | 0.120 |
Why?
|
| Premedication | 2 | 2005 | 44 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 4957 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2014 | 231 | 0.120 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 202 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1389 | 0.110 |
Why?
|
| Cardiotonic Agents | 2 | 2014 | 134 | 0.110 |
Why?
|
| Pregnancy Complications | 2 | 2017 | 478 | 0.110 |
Why?
|
| Publications | 1 | 2013 | 31 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1049 | 0.110 |
Why?
|
| Global Health | 1 | 2017 | 537 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 568 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2020 | 1137 | 0.100 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 234 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 201 | 0.100 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 202 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2016 | 539 | 0.100 |
Why?
|
| Logistic Models | 2 | 2014 | 1741 | 0.100 |
Why?
|
| Animals | 4 | 2024 | 33472 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 378 | 0.100 |
Why?
|
| Texas | 3 | 2015 | 3508 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 171 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 3266 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 1144 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 250 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1263 | 0.100 |
Why?
|
| Quality Control | 1 | 2011 | 117 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1089 | 0.090 |
Why?
|
| California | 1 | 2010 | 120 | 0.090 |
Why?
|
| Registries | 2 | 2019 | 1336 | 0.090 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 75 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1329 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 85 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2009 | 31 | 0.080 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 773 | 0.080 |
Why?
|
| Reperfusion | 1 | 2009 | 23 | 0.080 |
Why?
|
| Pressure | 1 | 2009 | 128 | 0.080 |
Why?
|
| Biomarkers | 2 | 2014 | 2919 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 75 | 0.080 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 168 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 204 | 0.070 |
Why?
|
| Obesity | 1 | 2017 | 2080 | 0.070 |
Why?
|
| Incidence | 1 | 2014 | 2965 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 365 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2005 | 91 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1199 | 0.060 |
Why?
|
| Linear Models | 2 | 2017 | 654 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1230 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2024 | 31 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 1258 | 0.050 |
Why?
|
| Central Venous Pressure | 1 | 2022 | 24 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 375 | 0.050 |
Why?
|
| Troponin I | 1 | 2003 | 98 | 0.050 |
Why?
|
| Prognosis | 1 | 2011 | 4472 | 0.050 |
Why?
|
| Phentolamine | 1 | 2021 | 20 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2021 | 21 | 0.050 |
Why?
|
| Morbidity | 2 | 2015 | 236 | 0.050 |
Why?
|
| Japan | 1 | 2020 | 131 | 0.050 |
Why?
|
| Complement C3a | 1 | 2000 | 20 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2003 | 1542 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 147 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 91 | 0.040 |
Why?
|
| Body Temperature | 1 | 2000 | 102 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2000 | 245 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 423 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 207 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2020 | 102 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 396 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 446 | 0.040 |
Why?
|
| Neutrophils | 1 | 2000 | 382 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2017 | 58 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 673 | 0.040 |
Why?
|
| Furosemide | 1 | 2016 | 36 | 0.030 |
Why?
|
| Down Syndrome | 1 | 2019 | 193 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 255 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 437 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 221 | 0.030 |
Why?
|
| Bradycardia | 1 | 2014 | 62 | 0.030 |
Why?
|
| Pregnancy | 2 | 2017 | 6858 | 0.030 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 28363 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1139 | 0.030 |
Why?
|
| Gases | 1 | 2012 | 15 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 227 | 0.030 |
Why?
|
| Missouri | 1 | 2012 | 36 | 0.030 |
Why?
|
| Troponin | 1 | 2012 | 70 | 0.030 |
Why?
|
| Catheterization | 1 | 2014 | 236 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 191 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 651 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 1451 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 798 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 367 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 1381 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2014 | 932 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 581 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1352 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1968 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2005 | 280 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 8627 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2005 | 194 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 18399 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 412 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 995 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 25263 | 0.010 |
Why?
|